Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Payables (2017 - 2026)

Organogenesis Holdings has reported Payables over the past 9 years, most recently at $31.9 million for Q4 2025.

  • For Q4 2025, Payables rose 10.51% year-over-year to $31.9 million; the TTM value through Dec 2025 reached $31.9 million, up 10.51%, while the annual FY2025 figure was $31.9 million, 10.51% up from the prior year.
  • Payables for Q4 2025 was $31.9 million at Organogenesis Holdings, down from $40.2 million in the prior quarter.
  • Over five years, Payables peaked at $40.2 million in Q3 2025 and troughed at $23.2 million in Q1 2024.
  • A 5-year average of $29.5 million and a median of $29.1 million in 2021 define the central range for Payables.
  • Biggest five-year swings in Payables: decreased 29.43% in 2023 and later skyrocketed 67.78% in 2025.
  • Year by year, Payables stood at $29.3 million in 2021, then rose by 10.19% to $32.3 million in 2022, then dropped by 4.97% to $30.7 million in 2023, then decreased by 5.9% to $28.9 million in 2024, then rose by 10.51% to $31.9 million in 2025.
  • Business Quant data shows Payables for ORGO at $31.9 million in Q4 2025, $40.2 million in Q3 2025, and $29.7 million in Q2 2025.